Navigation Links
Significant reductions in mortality shown using blood pressure-lowering treatment in very elderly
Date:3/31/2008

Lowering the blood pressure of elderly patients could cut their total mortality by a fifth and their rate of cardiovascular events by a third, according to a new study presented today (Monday 31 March) at the American College of Cardiology in Chicago and published simultaneously in the New England Journal of Medicine.

The 3,845 patient Hypertension in the Very Elderly Trial (HYVET), which is coordinated by scientists from Imperial College London, is the largest ever clinical trial to look at the effects of lowering blood pressure solely in those aged 80 and over. Patients were given either a placebo or the diuretic indapamide slow release (SR) 1.5mg, with the addition of the ACE inhibitor perindopril in tablet form once a day.

The research shows that the benefits of treatment include a 21% (p=0.02) reduction in total mortality rate, a 39% (p=0.05) reduction in stroke mortality rate, a 64% (p<0.001) reduction in fatal and non-fatal heart failures and a 34% (p<0.001) reduction in cardiovascular events. The benefits were apparent within the first year of follow-up.

The reduction in overall mortality was a novel and unexpected result. Earlier trials had demonstrated that reducing blood pressure in the under-80s reduces stroke and cardiovascular events. However, previous smaller and inconclusive studies also suggested that whilst lowering blood pressure in those aged 80 or over reduced the number of strokes, it did not reduce, and even possibly increased, total mortality.

In July 2007 the trial was stopped early on the recommendation of an independent data monitoring committee after they observed significant reductions in overall mortality and stroke in those receiving treatment. The final results of the trial showed a significant reduction in stroke mortality rate, but the reduction in all strokes of 30% did not quite reach statistical significance (p=0.06) In those aged 80 and over, up to half of strokes are fatal and the reduction in fatal strokes is an important finding.

Emeritus Professor Christopher Bulpitt, the lead investigator on the study from the Care of the Elderly Group at Imperial College London, said: "Before our study, doctors were unsure about whether very elderly people with high blood pressure could see the same benefits from treatment to lower their blood pressure as those we see in younger people. Our results clearly show that many patients aged 80 and over could benefit greatly from treatment. Populations are living longer and we have growing numbers of people living well into their 80s and beyond, so this is good news. We are very pleased that cardiovascular events were reduced safely with a reduction in total mortality."

The researchers hope that their findings will clear up uncertainty amongst clinicians about the benefits of treating those aged 80 and over for high blood pressure.

Dr Nigel Beckett, the trial co-ordinator from the Care of the Elderly Group at Imperial College London, added: "Many very elderly people with high blood pressure are not being treated for it at the moment, because doctors are unsure about whether or not treatment will help them. We hope that following our study, doctors will be encouraged to treat such patients in accordance with our protocol."

As the trial was stopped early, an extension involving patients receiving active-treatment is now underway to assess the longer term benefits of treatment.

Patients with high blood pressure (defined here as a systolic blood pressure between 160-199 mmHg), from thirteen countries across the world, were randomised for the double-blind, placebo-controlled trial, which began in 2001. The mean age of participants was 83 years and 7 months.

Patients were given either placebo or indapamide slow release (SR) with the addition of perindopril, in tablet form once a day as required, to achieve a target blood pressure of 150/80mmHg. The average follow-up of patients was just over 2 years by which time 20% of the placebo subjects and 48% of those taking medication had achieved the target blood pressure of 150/80 mmHg. In those patients who were followed up for longer, a larger number of patients receiving active treatment achieved the target blood pressure


'/>"/>

Contact: Laura Gallagher
L.Gallagher@imperial.ac.uk
44-078-038-86248
Imperial College London
Source:Eurekalert

Related medicine news :

1. MedCom Announces Card Activation Wins Significant Court Ruling
2. Significant Generic Erosion Will Cause Sales of Dyslipidemia Drugs to Decline by $3.6 Billion by 2016
3. Carnegie Mellon study shows just listening to cell phones significantly impairs drivers
4. NeurogesX to Present at Susquehanna Financial Groups 2nd Annual SIGnificant Options in Healthcare Conference
5. Novavax CEO to Present at Susquehannas Second SIGnificant Options in Healthcare Conference
6. Abaxis, Inc. to Present at the Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
7. Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
8. Advanced Life Sciences to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference
9. Significant Growth for Pinstripe Leads to Need for Larger Facility
10. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
11. AAAS symposium to address significant effects of the male parent in reproductive success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... March 30, 2017 , ... ... educational offerings of corporate finance programs to address the increasingly complex educational needs ... executives increase their knowledge of sophisticated corporate finance and will increase their ability ...
(Date:3/30/2017)... ... March 30, 2017 , ... ... of Nutrition and Dietetics (AND), will join nonprofit Seafood Nutrition Partnership (SNP) in ... live webinar designed to help nutrition educators and students inform consumers about the ...
(Date:3/29/2017)... ... 2017 , ... During the last week of March, Chad Kawa, MD of ... in the local community. , Colon cancer is the second leading cause of ... while it is small, confined and easier to treat. If you are 50 or ...
(Date:3/29/2017)... City, NY (PRWEB) , ... March 29, 2017 ... ... for men’s and women’s professional squash, announced it has enlisted New York City-based ... The agency will develop and procure sponsorship opportunities for the Professional Squash ...
(Date:3/29/2017)... MD (PRWEB) , ... March 30, 2017 , ... CHARM ... Charm City Run has announced that Mercy Medical Center will serve as the official ... the Mid-Atlantic region. On Sunday, June 25, 2017, thousands of women will walk or ...
Breaking Medicine News(10 mins):
(Date:3/30/2017)... YORK , March 30, 2017  Purcell Julie & ... shareholders nationwide, is investigating a potential breach of fiduciary duty ... (NASDAQ: SGYP ). If you ... obtaining additional information regarding this investigation, free of charge, please ... ...
(Date:3/29/2017)... Wound care devices and products are used ... The industry mainly consists of establishments engaged in manufacturing ... wounds caused by mechanical, chemical, thermal, and radiogenic trauma; ... diabetes, skin related diseases, immunological diseases, and other chronic ... the largest region in the wound care devices market ...
(Date:3/29/2017)... 2017 Global intravenous (IV) iron and oral iron ... growing at a CAGR of 5%. Iron ... to treat anemia or other iron deficiencies. Oral iron supplements ... However, in some cases, oral administrations are not capable of ... iron therapy comes into the picture. Global Intravenous ...
Breaking Medicine Technology: